
natera™
Better, together.
Natera Women's Health
Family of Genetic Tests

# Everything you need from a name you can trust.

For your patients, you demand precision and accuracy. For your practice, you need ease. With our Women's Health family of products, both are within reach.

From planning a family and prenatal testing to hereditary cancer screening, Natera offers high-quality genetic testing for women's health needs.

## Your unified solution for the top performing genetic tests in women's health

**Panorama™**
Next-generation NIPT

**Horizon™**
Advanced carrier screening

**Fetal Focus™**
NIPT for inherited conditions

**Empower™**
Hereditary cancer test

**Vistara™**
Single-gene NIPT

**Anora™**
Miscarriage test (POC)

natera™

Born from a personal mission, Natera revolutionized prenatal testing by pioneering unique single-nucleotide polymorphism (SNP)-based cell-free DNA (cfDNA) technology.

Backed by scientific data and clinical evidence, Natera created what is now the #1 ordered noninvasive prenatal test (NIPT) in the market.[1,4-31]

With continued innovation, Natera has delivered a complete women's health portfolio and applied cfDNA expertise across organ health and oncology.

**16M+**
tests performed[2]

**20+**
years of continued innovation

**400+**
peer-reviewed publications[3]

**1M+**
families provided with pregnancy information each year[2]

*In 2004, my sister gave birth to a son with Down syndrome. He passed away six days after birth. It was a devastating experience for our entire family. We wish we could have been better prepared.*

***I founded Natera because I believe all families deserve access to technologies that offer early detection of genetic disease.***

*We started with reproductive genetic screening, and now we're applying our expertise to early detection of cancer recurrence and organ transplant rejections."*

**MATTHEW RABINOWITZ**
**FOUNDER OF NATERA**

natera | Panorama™ Next-generation NIPT

# Pioneering technology powering the #1 NIPT

Panorama™ NIPT uses cfDNA and unique SNP-based technology to deliver comprehensive, accurate, and reliable prenatal screening.[1, 4-15]

Panorama™ can screen for the following conditions as early as nine weeks:

**Whole-chromosome conditions**

- Trisomy 21, 18, 13
- Monosomy X
- Sex chromosome trisomies
- Triploidy

**Optional add-ons**

- 22q11.2 deletion syndrome
- Additional microdeletions
- Fetal sex
- Fetal RhD status

> "With **40+** peer-reviewed publications and **2 million+** patients included in publications, Panorama™ is thoroughly validated with scientific rigor."[17]

## Continued innovation drives enhanced capabilities




## The ability to distinguish maternal from fetal DNA enables unique, clinically validated capabilities and highly accurate results




SMART
SNP-based Microdeletion and Aneuploidy RegIsTry

Panorama™ is the *only NIPT* validated in a prospective study where genetic confirmation of outcomes was collected on all patients in the analysis.[29-31]

- >20,000 patients (>70% "average risk") enrolled
- Strong clinical performance of aneuploidy* and 22q11.2 deletion screening confirmed in real-world population

* Common trisomies and sex chromosome aneuploidies

**Scan for all Panorama™ performance metrics**

## Choose the best-in-class 22q detection test

**Add On: 22q Deletion Screening**

**22q11.2 deletion syndrome (DiGeorge syndrome) is common and not often detected prenatally**

22q is associated with congenital heart defects, palatal anomalies, hypocalcemia, and neurodevelopment disorders[29, 32-35]




- There are no standardized newborn screening protocols
- Maternal age is not a risk factor

**Panorama™ has the highest published clinical sensitivity of any NIPT:**** 83% to detect 8/10 affected pregnancies[23]

** Clinical validation studies are those with pregnancy samples and confirmed outcomes for all cases included in the study. Clinical sensitivity and specificity defined as: sensitivity = true positives / (true positives + false negatives), specificity = true negatives / (true negatives + false positives).

Hear one family's story

**Scan to learn more**

## Get highly accurate fetal RhD status

**Add On: Fetal RhD NIPT**

**The largest fetal RhD NIPT clinical validation study with confirmed outcomes for 655 Rh- patients[41]**

100% Sensitivity† | >99% Specificity

† Performance reported for study samples. In clinical practice, false negatives and false positives may occur.

> "Up to 40% of Rh D-negative pregnant women will carry an Rh D-negative fetus. In this clinical situation, antenatal anti-D immune globulin administration is unnecessary."
>
> **– ACOG Practice Bulletin 181: Prevention of Rh D Alloimmunization.[42]**

Add Fetal RhD NIPT into your practice

**Scan to learn more**

natera™ | Horizon™
Advanced carrier screening

# Broad carrier screening with unmatched support

Horizon™ carrier screening leverages next-generation sequencing technology to give your patients comprehensive information about their risk of passing on serious genetic conditions. Horizon™ uniquely combines actionable results with support resources tailored for your patients and practice.

## Know risks for serious conditions earlier

88%

**Family history is not a predictor**

88% of carriers of cystic fibrosis, spinal muscular atrophy, and fragile X syndrome have no known family history[43]

**Newborn screening (NBS) alone is not sufficient**

Conditions screened by NBS vary by state, and results can return too late

**Early treatment can make a difference**

Carrier screening enables early treatment, which can change the trajectory of a condition

**ACOG says...**

> Information about genetic carrier screening should be provided to every pregnant woman."[44]

## Screen for clinically actionable conditions to better prepare

| Condition category and examples | | | | |
|---|---|---|---|---|
| **Conditions newborn screening may miss** | **Conditions with FDA-approved pediatric therapies** | **X-linked conditions** | **Metabolic conditions** | **Conditions with in-utero treatments** |
| Cystic Fibrosis *(CFTR)*<br>Newborn screening for cystic fibrosis can have lower detection rates in non-White populations, leading to delayed diagnosis and care[45] | Spinal Muscular Atrophy *(SMN1)*<br>Before onset of symptoms, treatments such as gene therapy Zolgensma™ can make a significant difference in ability to walk independently[46-48] | Duchenne Muscular Dystrophy *(DMD)*<br>Treatments, including gene therapy Elevidys®, can help slow progression of muscle loss, maintain quality of life, and prolong survival[49,50] | Galactosemia *(GALT)*<br>Simple diet modification can prevent profound intellectual disability and life-threatening complications that can appear within days after birth[51] | Alpha-Thalassemia *(HBA1/HBA2)*<br>Intrauterine transfusion can be used to enable survival and improve neurodevelopmental outcomes in fetuses with alpha thalassemia major[52] |

Included on Horizon™ 4 pan-ethnic basic panel

Included on Horizon™ 14 pan-ethnic standard panel

**Scan for full conditions list**

## Offer Horizon's customizable panels and support services

**Exceptional breadth and flexibility—** thoughtfully designed panels screen up to 835 conditions.

**Horizon 4**
*Pan-ethnic basic:* CF, SMA, fragile X, Duchenne muscular dystrophy

**Horizon 14**
*Pan-ethnic standard:* Includes hemoglobinopathies

**Horizon 27**
*Pan-ethnic medium*

**Horizon 274**
*Pan-ethnic extended*

**Horizon 421**
*Pan-ethnic expanded*

**Horizon Custom**
Up to 835 conditions, including all 113 ACMG-recommended genes[56]

Cystic fibrosis (CF), spinal muscular atrophy (SMA), fragile X, Duchenne muscular dystrophy (DMD), and Tay-Sachs enzyme can be ordered individually.

**High detection rates—** advanced technology detects more carriers.

**Cystic Fibrosis**
Targeted analysis can miss up to **44%** of carriers detected by Horizon™.[53]

**ACOG says...**
*"A number of expanded mutation panels … can be considered to enhance sensitivity for carrier detection, especially in non-Caucasian ethnic groups."*[44]

**Spinal Muscular Atrophy**
Traditional screening[54] misses **~60%** of patients Horizon™ identifies as at-risk.[53]

**ACOG says...**
*"[A subset] of the general population … will not be identified as being a carrier … using [traditional methods]."*[44]

**Hemoglobinopathies**
CBC and electrophoresis testing alone could miss **90% of alpha-** and **6% of beta-**hemoglobinopathy carriers detected by Horizon™.[53]

**ACOG says...**
*"Hemoglobinopathy testing may be performed using hemoglobin electrophoresis or molecular genetic testing."*[55]

**Comprehensive support—** tools and services to meet clinician and patient needs.

**Partner testing resources**
Partner auto-enroll, partner kit and order form, and joint reports streamline partner testing workflow. NEVA* also discusses partner testing and collects partner information from positive carriers.

**Results delivery**
NEVA* delivers 24/7 results support with over 400 condition-specific educational videos and refers patients to our complimentary GIS*. Both NEVA and GIS are available in Spanish.

*NEVA = Natera's Educational Virtual Assistant
GIS = Genetic Information Sessions

natera™ | Fetal Focus™
NIPT for inherited conditions

# The next-generation single-gene NIPT

Fetal Focus™ single-gene NIPT screens the fetus for inherited conditions using cfDNA from the maternal carrier's sample. After Horizon™ identifies the pregnant patient as a carrier, Fetal Focus™ assesses fetal risk for up to 21 genes.

## Directly screen the fetus from the pregnant Horizon™ carrier's sample

Assess fetal risk for inherited single-gene conditions without a partner sample

**Up to 75% of partners** of carriers do not complete testing[57-60]

Screen the fetus for up to 21 serious, clinically actionable genes

**1 in 470 pregnancies** are affected by one of the Fetal Focus™ conditions[53]

Enable earlier diagnosis and treatment for at-risk fetuses

**All conditions screened have treatments** that can improve a baby's wellbeing

## Enable early perinatal interventions for 21 recessive and X-linked genes

| | FDA-approved interventional newborn treatments | Dietary modifications or supplements | Management that reduces complications or supports development | FDA-approved or investigational in-utero treatments |
|---|---|---|---|---|
| Included on Horizon™ 14 pan-ethnic standard panel | Alpha-thalassemia (*HBA1/2*)<br>Beta-hemoglobinopathies including sickle cell disease (*HBB*)<br>Cystic fibrosis (*CFTR*)<br>Duchenne muscular dystrophy (*DMD*)*<br>**Gaucher disease (*GBA*)**<br>Spinal muscular atrophy (*SMN1*) | **Galactosemia (*GALT*)**<br>Medium-chain acyl-CoA dehydrogenase deficiency (*ACADM*)<br>Smith-Lemli-Opitz syndrome (*DHCR7*) | Canavan disease (*ASPA*)<br>Familial dysautonomia (*IKBKAP*)<br>Fragile X syndrome (*FMR1*)*<br>**Polycystic kidney disease (AR) (*PKHD1*)**<br>Tay-Sachs disease (*HEXA*) | Alpha-thalassemia (*HBA1/2*)<br>Cystic fibrosis (*CFTR*)<br>**Gaucher disease (*GBA*)**<br>Spinal muscular atrophy (*SMN1*) |
| | **Glycogen storage disease Type 2 (Pompe disease) (*GAA*)**<br>**Krabbe disease (*GALC*)** | **Carnitine palmitoyltransferase II deficiency (*CPT2*)**<br>**Familial mediterranean fever (*MEFV*)**<br>Phenylketonuria (*PAH*) | **Wilson disease (*ATP7B*)** | **Glycogen storage disease Type 2 (Pompe disease) (*GAA*)** |

**Conditions in bold indicate Fetal Focus™ is the only single-gene NIPT that offers fetal cfDNA screening for this condition.**

*Fetal risk assessment for X-linked conditions is based on fetal sex only. Fetal Focus™ does not directly screen the fetal *DMD* or *FMR1* genes.

natera™ | Empower™
Hereditary cancer test

# Hereditary cancer testing, simplified

Empower™ is a genetic test for those who want to know more about their risk for developing cancer or why cancer might be common in their family. Empower™ includes genes associated with increased risk of hereditary cancers, with panel options to suit your preferred screening strategy.

## Panel options with up to 81 genes across 12+ common hereditary cancer types

Breast | Ovarian | Uterine | Colorectal | Gastric | Prostate | Pancreatic | Melanoma | Renal

| BRCA1 & BRCA2 panel | Lynch syndrome panel | GYN guidelines-based panel | Multi-cancer panel | Comprehensive panel |
|---|---|---|---|---|
| **2** total genes | **5** total genes | **19** total genes | **40** total genes | **81** total genes |

## Empower™ is delivered with clinical rigor, including DNA and RNA analysis

DEVELOPED IN PARTNERSHIP WITH BAYLOR GENETICS

- An expert curation team classifies variants according to American College of Medical Genetics (ACMG) guidelines.
- Baylor Genetics regularly contributes clinically significant variants to ClinVar public database for the benefit of patients and the medical community.
- RNA analysis is performed for VUSs at splice site regions with no additional sample, no additional time, and no additional cost.

## Natera offers support tools for busy providers

### Actionable Reports

Information to guide management decisions based on the latest medical guidelines

### Family Testing Program

Testing for blood relatives of patients with a positive result is available at no additional charge*

### NEVA NOW IN SPANISH

- Enables streamlined pretest family cancer history intake
- Provides interactive results delivery and education after testing

* Any order must be received within 180 days of original report date. Panel ordered must be the same size or smaller compared to positive relative's test. Not available to patients covered by government insurance plans

natera™ | Vistara™
Single-gene NIPT

# Deeper insights for earlier detection

Vistara™ screens cfDNA for serious autosomal dominant or X-linked single-gene conditions that affect quality of life, could benefit from early intervention, and could have otherwise gone undetected.




## Vistara™ provides a deeper level of clinically actionable information

**>99% sensitivity and specificity** based on clinical validation published in *Nature Medicine*[61]

### Vistara™ screens for:

**25 conditions** across 30 genes, including skeletal, cardiac, and neurological disorders

**Conditions not reliably detected** by existing modalities

**Conditions requiring significant changes** to labor or delivery management and neonatal interventions or surgery

### Consider Vistara™ for:

**Biological partner of advanced age (40+)**[62]

**Ultrasound anomalies**

**Family history of hereditary conditions**

**Pregnant patients who want to know as much as possible, noninvasively**

natera™ | Anora™
Miscarriage test (POC)

# Highly comprehensive miscarriage test

For more than a decade, Anora™ has been used to determine whether a chromosomal abnormality was the likely cause of a miscarriage.

Results can help explain why a miscarriage occurred and, possibly, whether your patient is at increased risk for a chromosomal abnormality in a future pregnancy. For many patients, this knowledge can help ease their emotional burden and inform reproductive decisions moving forward.

### Anora™ miscarriage test can detect:

**Aneuploidy and triploidy**

**Deletions and duplications >5 Mb and down to 1 Mb if clinically significant**

**Uniparental disomy (UPD)**

## SNP-based technology delivers more

Anora™ uses sophisticated SNP-based microarray analysis to offer clear advantages over traditional products of conception (POC) testing methods.[63]

**Identifies parental origin** of chromosomal abnormalities* to inform reproductive and post-pregnancy care

**Detects partial and complete molar pregnancies,** which require medical follow-up

**Rules out maternal cell contamination (MCC)** from a normal female fetal result

**Provides a result† >99%** of the time, versus a 10%–40% chance of no results with karyotyping[64,65]

**Delivers results in about one week,** versus two to five weeks for karyotyping

* When a parental blood or buccal sample is submitted
† Includes MCC results

# Increase insight, not effort

## Virtual and on-site teams when you need it, with hassle-free digital solutions

### A selection of our NateraCore offerings

### Genetic education on demand

**Complimentary genetic information sessions** before and after testing.

**Educational videos** can be sent to patients before an appointment.

**Natera Academy** educational resources built by board-certified genetic counselors.

### Results delivered conveniently

**Natera's Educational Virtual Assistant (NEVA)** delivers 24/7 genetic education and guidance for results. Available in Spanish.

**Fetal sex reporting** shares fetal sex results with others.

**High-risk results notifications** notify providers of high risk and positive results via email to support timely patient care.

### Accessible testing for all patients

**Flexible phlebotomy options** from in-office phlebotomy support (where permitted) to mobile phlebotomy for draws at home.

**Financial access programs** include pre-test cost estimates and reduced cost for qualified patients.

**Price Transparency Program*** proactively contacts patients if out-of-pocket cost estimates exceed the cash price; self pay option available.

* If contact information is available, and as authorized by the patient consistent with Natera Privacy.

**References**


1. Nicolaides et al. *Prenat Diagn.* 2013;33(6):575-9.
2. Natera internal data as of 12/31/25.
3. Natera internal data as of 02/26/26.
4. Pergament et al. *Obstet Gynecol.* 2014;124(2 Pt 1):210-8.
5. Ryan et al. *Fetal Diagn Ther.* 2016;40(3):219-223.
6. Stokowski et al. *Prenat Diagn.* 2015;35(12):1243-6.
7. Jones et al. *Ultrasound Obstet Gynecol.* 2018;51(2):275-276.
8. Palomaki et al. *Genet Med.* 2011;13(11):913-20.
9. Palomaki et al. *Genet Med.* 2012;14(3):296-305.
10. Porreco et al. *Am J Obstet Gynecol.* 2014;211:365.e1-12.
11. Mazloom et al. *Prenat Diagn.* 2013;33(6):591-7.
12. Sehnert et al. *Clin Chem.* 2011;57(7):1042-1049.
13. Bianchi et al. *Obstet Gynecol.* 2012;119(5):890-901.
14. Bianchi et al. *N Engl J Med.* 2014;370:799-808.
15. Verinata white paper. Analytical validation of the Verifi prenatal test. 2012.
16. ACOG Practice Advisory: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol. 2026 Jan; 147(1):p 139.
17. Natera internal data on file.
18. Benn et al. *Prenat Diagn*. 2024 Sept; 44(10):1218-1224.
19. Pergament et al. *Obstet Gynecol.* 2014 Aug;124(2 Pt 1):210-8.
20. Nicolaides et al. *Prenat Diagn.* 2013 June; 33(6):575-9.
21. Ryan et al. *Fetal Diagn Ther.* 2016; 40(3):219-223.
22. Norwitz et al. *J Clin Med.* 2019 Jun; 8:937.
23. Dar et al. *Am J Obstet Gynecol*. 2022 Jul; 227(1):79.e1-11.
24. Hedriana et al. *Prenat Diagn.* 2020 Jan; 40(2):179-84.
25. Curnow et al. *Am J Obstet Gynecol.* 2015 Jan; 212(1):79.e1-9.
26. Kantor et al. *Prenat Diagn.* 2022 Jul; 42(8):994-999.
27. Nicolaides et al. *Fetal Diagn Ther.* 2014. 35;(3):212-7.
28. Martin et al. *Am J Obstet Gynecol MFM.* 2020; 2:100152.
29. Dar et al. *Am J Obstet Gynecol*. 2022 Aug;227(2):259.e1-259.e14.
30. Dar et al. *Am J Obstet Gynecol*. 2022 Jul;227(1):79.e1-79.e11.
31. Norton et al. *Am J Obstet Gynecol*. 2023 Sep;229(3):300.e1-300.e9.
32. Bassett et al. *J Pediatr*. 2011;159(2): 332-339.
33. Cheung et al. *Genet Med*. 2014;16(1):40-44.
34. Grand et al. *Am J Med Genet A*. 2018;176(10):2167-2171.
35. Palmer et al. *Am J Med Genet A*. 2018;176(4):936-944.
36. Snijders et al. *Ultrasound Obstet Gynecol*. 1999;13(3):167-170.
37. Blagojevic et al. *CMAJ Open*. 2021 Aug 17;9(3):E802-E809.
38. Hamosh et al. *J Pediatr.* 1998;132(2):255-259.
39. O'Sullivan, Freedman. *Lancet*. 2009;373(9678):1891-1904.
40. Snijders et al. *Fetal Diagn Ther*. 1995 Nov-Dec; 10(6):356-67.
41. Gilstrop Thompson et al. *Obstet Gynecol*. 2025;145(2):211-216
42. ACOG. Practice Bulletin 181: Prevention of Rh D Alloimmunization. 2017.
43. Archibald et al. *Genet Med*. 2018;20:513-523.
44. ACOG Committee Opinion 691. March 2017.
45. McGarry et al. *Pediatr Pulmonol*. 2023 Feb;58(2):465-474.
46. Lin et al. *Pediatr Neurol*. 2015 Oct;53(4):293-300.
47. Sumner et al. *Nat Med*. 2022 Jul;28(7):1348-1349.
48. Dangouloff et al. *Ther Clin Risk Manag*. 2019 Oct 2;15:1153-1161.
49. Wong et al. *Eur J Hum Genet*. 2015 Oct;23(10):1294-300.
50. Bourke et al. *Open Heart*. 2022 Oct;9(2):e001977.
51. Pyhtila et al. *JIMD Rep*. 2015;15:79-93. doi: 10.1007/8904_2014_302.
52. Schwab et al. *Blood Adv*. 2023 Jan 24;7(2):269-279.
53. Westemeyer et al. *Genet Med*. 2020;22(8):1320-1328.
54. Prior and Professional Practice Guidelines Committee. *Genet Med*. 2008;10:840–842.
55. Hemoglobinopathies in Pregnancy. ACOG Practice Advisory. Aug 2022.
56. Gregg et al. *Genet Med*. 2021 Oct;23(10):1793-1806.
57. Nguyen et al. *Genet Med Open*. 2023 Sep 1;1(1):100831.
58. Choates et al. *Prenat Diagn*. 2020 Feb;40(3):311-316.
59. Arjunan et al. *Prenat Diagn*. 2021 Jun;41(7):896-904.
60. Taber et al. *Genet Med*. 2019 May;21(5):1041-1048.
61. Zhang et al. *Nat Med*. 2019;25(3):439-447.
62. Toriello et al. *Genet Med*. 2008;10(6):457-60.
63. Shah et al. *Fertil Steril*. 2017;107(4):1028-1033.
64. Levy et al. *Obstet Gynecol*. 2014;123 (2 pt1):202-9.
65. Bell et al. *Fertil Steril*. 1999.71(2):334–41.



**13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com**




natera™